SB203580 (Adezmapimod) in Oncology and Cancer Research
SB203580 (Adezmapimod) is a small molecule inhibitor of the mitogen‑activated protein kinase (MAPK) pathway with potential applications in oncology, particularly in nasopharyngeal carcinoma (NPC).
SB203580 (Adezmapimod) is a small molecule inhibitor of the mitogen‑activated protein kinase (MAPK) pathway with potential applications in oncology, particularly in nasopharyngeal carcinoma (NPC).
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- Anti‑PD‑1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double‑blind phase 3 study
- Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma
- Nasopharyngeal Cancer
- Hierarchical dynamic model for risk‑stratified screening of nasopharyngeal carcinoma
- Expert consensus on the role of immunotherapy in nasopharyngeal carcinoma: clinical and economic perspectives from the GCC region